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Streptococcus pneumoniae colonization of the respiratory tract is an essential precursor for
pneumococcal disease. To colonize efficiently, bacteria must adhere to the epithelial-cell surface.
S. pneumoniae possesses surface-associated exoglycosidases that are capable of sequentially
deglycosylating human glycans. Two exoglycosidases, neuraminidase (NanA) and
b-galactosidase (BgaA), have previously been shown to contribute to S. pneumoniae adherence
to human epithelial cells, as deletion of either of these genes results in reduced adherence. It has
been suggested that these enzymes may modulate adherence by cleaving sugars to reveal a
receptor on host cells. Pretreatment of epithelial cells with exogenous neuraminidase restores the
adherence of a nanA mutant, whereas pretreatment with b-galactosidase does not restore the
adherence of a bgaA mutant. These data suggest that BgaA may not function to reveal a receptor,
and implicate an alternative role for BgaA in adherence. Here we demonstrate that
b-galactosidase activity is not required for BgaA-mediated adherence. Addition of recombinant
BgaA (rBgaA) to adherence assays and pretreatment of epithelial cells with rBgaA both
significantly reduced the level of adherence of the parental strain, but not the BgaA mutant. One
possible explanation of these data is that BgaA is acting as an adhesin and that rBgaA is binding
to the receptor, preventing bacterial binding. A bead-binding assay demonstrated that BgaA can
bind directly to human epithelial cells, supporting the hypothesis that BgaA is an adhesin.
Preliminary characterization of the epithelial-cell receptor suggests that it is a glycan in the context
of a glycosphingolipid. To further establish the relevance of this adherence mechanism, we
demonstrated that BgaA-mediated adherence contributed to adherence of a recent clinical isolate
to primary human epithelial cells. Together, these data suggest a novel role for BgaA as an
adhesin and suggest that this mechanism could contribute to adherence of at least some
pneumococcal strains in vivo.
INTRODUCTION
Streptococcus pneumoniae is a major human pathogen,
causing diseases ranging in severity from otitis media and
sinusitis to pneumonia, bacteraemia and meningitis (Fine
et al.,1996; Leibermanet al.,2001).Pneumococci frequently
colonize the nasopharynx asymptomatically (Denno et al.,
2002; Watt et al., 2004) and, in the majority of cases, are
cleared by the host. Sometimes, however, bacteria can
spread to normally sterile sites where they are able to cause
disease.
Colonization is an essential step in pneumococcal patho-
genesis, but little is known about the mechanisms by which
itisestablishedandmaintained.Pneumococcaladherenceto
the epithelial-cell surface is known to play an important role
in colonization, and several mechanisms of pneumococcal
adherence have already been identified. It is likely, however,
that adherence is multifactorial and tissue-specific, and
requires additional factors that have yet to be identified
(Cundell et al., 1995b; Zhang et al., 2000; reviewed by
Hammerschmidt, 2006).
Manipulation of carbohydrates is central to the pneumo-
coccallifestyleandisa well-utilizedmechanismofadherence
Abbreviations: D562, Detroit 562 cells; Galb1,4GlcNAc, galactose
b(1–4)-linked to N-acetylglucosamine; LB, Luria–Bertani; NHBE, normal
human bronchial epithelial cells; PAFR, platelet-aggregating factor
receptor; rBgaA, recombinant BgaA.
3Present address: The Center for Microbial Interface Biology, The Ohio
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pneumoniae has evolved multiple methods to manipulate
carbohydrates, including: (i) production of .90 distinct
capsular polysaccharides, utilized to protect the organism
from opsonophagocytosis (Henrichsen, 1995; Jin et al.,
2009; Zartler et al., 2009); (ii) expression of numerous
proteins that enable the transport and utilization of
carbohydrates (Tettelin et al., 2001); and (iii) production
of at least eight surface-associated glycosidases that modify
host glycoconjugates (Berry et al., 1994; Bongaerts et al.,
2000; Caines et al., 2008; Ca ´mara et al., 1994; Clarke et al.,
1995; Jeong et al., 2009; King, 2010; Muramatsu et al., 2001;
Umemoto et al., 1977; Za ¨hner & Hakenbeck, 2000).
We demonstrated previously that S. pneumoniae can
deglycosylate complex N-linked glycans sequentially through
the activity of neuraminidase (NanA), b-galactosidase
(BgaA) and N-acetylglucosaminidase (StrH) (King et al.,
2006). Neuraminidase NanA is a surface-associated glycosi-
dase that cleaves a2,3- and a2,6-linked terminal sialic acids
from many different glycan structures, exposing other
carbohydrate residues. Several studies have proposed that
cleavage of terminal sialic acid by NanA may reveal a
receptor on the epithelial-cell surface. Tong et al. (1999)
demonstrated increased S. pneumoniae binding to neurami-
nidase-treated chinchilla tracheas, and pneumococcal adher-
ence to human epithelial cells was inhibited by addition of
sialylated glycoconjugates (Barthelson et al., 1998).
Furthermore, a nanA mutant was significantly reduced in
adherence to epithelial-cell lines and this deficiency was
restored by pretreatment with purified neuraminidase (King
et al.,2 0 0 6 ) .
The ability of S. pneumoniae to deglycosylate glycoconju-
gates sequentially suggests that other glycosidases may
contribute to the exposure of receptors by cleaving
carbohydrates revealed by NanA. Adherence assays using
bgaA and strH mutants revealed that bgaA, but not strH,
contribute significantly to adherence (King et al., 2006).
These data suggest that NanA and BgaA may be deglyco-
sylating a glycoconjugate sequentially to reveal an unknown
pneumococcal receptor. Furthermore, as NanA and BgaA,
but not StrH, were shown to be required for adherence, the
structure of the glycan receptor is most likely distinct from
complex N-glycan structures displayed on host glycopro-
teins that were shown previously to be deglycosylated
sequentially by these three enzymes (King et al., 2006).
Previously published work demonstrating that NanA and
BgaA, but not StrH, have increased expression during the
initial interaction of S. pneumoniae with human epithelial
cells supports a role for these two enzymes in the
establishment of colonization (Song et al., 2008).
BgaA is a 2228 aa protein that is secreted and attached to
the pneumococcal surface in a sortase-dependent manner
(Kharat & Tomasz, 2003; Za ¨hner & Hakenbeck, 2000). It is
the only b-galactosidase expressed by S. pneumoniae with
sequence similarity to Escherichia coli LacZ, although it is
over twice the size of this enzyme and the vast majority of
other bacterial b-galactosidases (1024 aa). This larger size
may suggest a secondary function for the protein.
Pneumococcal BgaA has high specificity for terminal
galactose b1,4-linked to N-acetylglucosamine (Galb1,
4GlcNAc), indicating that, unlike other characterized
b-galactosidases, the main role for BgaA is not in lactose
metabolism, but instead in deglycosylation of human
glycoconjugates (Za ¨hner & Hakenbeck, 2000; Zeleny et al.,
1997). The gene encoding BgaA is present in all available
genome sequences and antibodies to BgaA are found in
post-immune serum, suggesting that BgaA is expressed in
vivo during pneumococcal colonization or disease (Giefing
et al., 2008; Hoskins et al., 2001; Lanie et al., 2007; Tettelin
et al., 2001; Zysk et al., 2000).
In the present study, we demonstrate that the role of BgaA
in adherence is independent of its enzymic activity, and
present strong evidence that BgaA acts as a pneumococcal
adhesin. Furthermore, we demonstrate that this mech-
anism is relevant to the adherence of recent clinical isolates
to primary human epithelial cells.
METHODS
Bacterial strains, culture media and chemicals. Bacterial strains
used in this study are described in Table 1. C06_18 is a low-passage
strain isolated at Nationwide Children’s Hospital during 2005–2006. S.
pneumoniae was grown on tryptic soy (Becton Dickinson) plates with
1.5% agar, onto which 5000 U catalase (Worthington Biochemical)
was spread and incubated at 37 uCi n5%C O 2. Pneumococcal broth
cultures were grown in Todd–Hewitt broth supplemented with 0.2%
yeast extract (both from Becton Dickinson) (THY). Where appropri-
ate, medium was supplemented with streptomycin (200 mgm l
21),
kanamycin (500 mgm l
21) or erythromycin (1 mgm l
21). E. coli strains
TOP10 (Invitrogen Life Technologies) and XL1-Blue (Stratagene) were
grown and maintained in Luria–Bertani (LB) medium. When required,
LB was supplemented with ampicillin (100 mlm l
21), X-Gal
(80 mgm l
21) and IPTG (20 mM). All other chemicals, substrates
and enzymes, unless otherwise specified, were purchased from Sigma.
Mutation of nanA and bgaA. Insertion–deletion mutations were
generated as described previously and confirmed by PCR using primers
flanking the constructs (primers: nanA, N.1 and N.2, N.3 and N.4;
bgaA,B.1andB.2) (Table2)(Kingetal., 2004,2006).AllgenomicDNA
waspreparedasdescribedpreviously(Whatmoreetal., 1999). Thegene
encoding NanA is predicted to be in a single gene transcriptional unit
and BgaA is predicted to be the last gene in an operon, therefore polar
effects are probably irrelevant (Kaufman & Yother, 2007; Tettelin et al.,
2001). The bgaA mutant was genetically reconstituted by reintroducing
the deleted region into the same genetic location by transformation.
Replica plating of resulting colonies was performed to identify
erythromycin-sensitive transformants. The presence of the gene was
established by PCR and a b-galactosidase activity was used to confirm
that functional protein was expressed.
To generate an active-site mutant in BgaA, we performed site-directed
mutagenesis of nucleotide 1690 (GAC), which resulted in replace-
ment of glutamic acid-564 with a glutamine residue. A region of bgaA
flanking glutamic acid-564 was amplified from chromosomal DNA of
strain R6 using primers B.3 and B.4, cloned into pCR2.1-TOPO and
maintained in TOP10 cells. The presence of the insert was confirmed
by PCR (primers P.1 and P.2). In order to minimize PCR-generated
errors, all PCRs for mutant generation were conducted using a
D. H. Limoli and others
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from the resulting strain was prepared (Qiagen) and used as the
template for site-directed mutagenesis. The point mutation was
introduced using primers B.5 and B.6 and a QuikChange II site-
directed mutagenesis kit (Stratagene). Following the mutagenesis,
DNA was transformed into XL1-Blue supercompetent cells. The
presence of the point mutation and absence of other sequence
changes were confirmed by sequencing (primers B.3, B.4, B.7, B.8,
P.1 and P.2). To introduce the site-directed mutation into R6, we
utilized the Janus cassette selection system (Sung et al., 2001). DNA
fragments flanking the mutagenesis site were amplified (primers B.9
and B.10, and B.11 and B.4) and joined sequentially to the Janus
cassette PCR product (primers J.1 and J.2) using a variation on the
splicing by overlap extension by PCR process (Burnaugh et al.,
2008), first described by Horton et al. (1989). The Janus construct
was transformed into S. pneumoniae; transformants were selected
on kanamycin and confirmed by PCR (B.12 and B.13). These Janus
mutants were then transformed with the PCR product containing
the site-directed mutation. Generation of a strain containing the
desired mutation was confirmed by PCR with primers flanking the
construct (B.12 and B.13) and sequencing. None of the mutants
generated showed a significant reduction in growth rate or
maximum OD600 relative to the parent strain (data not shown).
As opacity can also affect adherence of S. pneumoniae,a l lm u t a n t s
were confirmed as being of the same opacity as their parental
strains (Cundell et al., 1995c; Gould & Weiser, 2002; Kim & Weiser,
1998).
Adherence of S. pneumoniae to human epithelial cells. The
adherence of S. pneumoniae to Detroit 562 cells (D562; ATCC
CCL-138), a human pharyngeal carcinoma cell line; A549 cells (ATCC
CCL-185), a human lung carcinoma cell line; 16HBE14, an
immortalized human bronchial epithelial cell line (Gruenert et al.,
1995); LA-4 cells (ATCC CCL-196), a mouse lung adenoma epithelial
cell line; and primary normal human bronchial epithelial (NHBE)
cells, was determined essentially as described previously (Gould &
Weiser, 2002; King et al., 2006). In brief, bacteria were grown in liquid
culture to an OD600 of 0.6, diluted in antibiotic-free tissue-culture
medium and, on average, 5610
4 bacteria per 1.9 cm
2 were added to a
confluent monolayer of epithelial cells. The bacteria were applied to
the epithelial cells by centrifugation (250 g for 5 min) and then
allowed to adhere at 37 uC for 60 min (no difference in adherence
was observed in control experiments in the absence of centrifugation).
To determine the percentage of the bacteria from the inoculum that
were adherent, non-adherent bacteria were removed by five washes in
PBS, and epithelial cells and adherent bacteria were lifted with 0.25%
trypsin/1 mM EDTA, vortexed and maintained at 4 uC. Bacteria were
enumerated by serial dilution. The percentage adherence of all strains
was calculated as the proportion of the inoculum that was adherent to
the epithelial cells. Adherence of the wild-type strains was adjusted to
100% and adherence of the mutants was expressed relative to that of
the parental strain under the same experimental conditions. All
adherence assays were performed in triplicate on at least three
independent occasions. Data are presented as means±SD of the
independent experiments.
This method was modified for NHBE cells, which were washed three
times instead of five after incubation with pneumococcal strains to
prevent lifting of epithelial cells. Means of at least three independent
experiments were used for statistical analysis. Where indicated, D562
cells were pretreated for 30 min with 0.01 U purified Clostridium
perfringens neuraminidase per 1.9 cm
2 well surface area. C. perfringens
neuraminidase has cleavage specificities the same as those of the
pneumococcal neuraminidase, NanA (Cassidy et al., 1965). Assays in
which the adherence of R6 was blocked by recombinant BgaA (rBgaA)
(QA Bio) were performed by adding 4.33 pmol (unless otherwise
indicated) rBgaA per 1.9 cm
2 well surface area with bacterial
Table 1. Strains used in this study
Cm
r, Resistant to chloramphenicol; Em
r, resistant to erythromycin; Sm
r, resistant to streptomycin, Tet
r, resistant to tetracycline;
UN, unencapsulated.
Strain name Serotype Characteristics/genotype Source or reference
Streptococcus pneumoniae
D39 2 Clinical isolate Iannelli et al. (1999)
R6 UN Unencapsulated varient of D39 Iannelli et al. (1999)
D39DbgaA 2 DbgaA (Em
r) King et al. (2006)
R6DbgaA UN DbgaA (Em
r) King et al. (2006)
R6DbgaA/bgaA
+ UN DbgaA/bgaA
+ This study
R6DnanA UN DnanA (Cm
r) King et al. (2006)
R6DnanADbgaA UN DnanA (Cm
r), DbgaA (Em
r) This study
R6DcbpA UN DcbpA (Em
r) Dr M. Bender
R6Sm
r UN rpsLK56T (Sm
r) This study
R6Sm
rDbgaA UN DbgaA (Em
r), rpsLK56T (Sm
r) This study
R6BgaAE564Q UN Gln564AGlu in BgaA, rpsLK56T (Sm
r) This study
C06_18 22F Clinical isolate from blood Burnaugh et al. (2008)
C06_18DbgaA 22F DbgaA (Em
r) This study
TIGR4 4 Clinical isolate Tettelin et al. (2001)
TIGR4DbgaA 4 DbgaA (Em
r) This study
384 6A Transparent variant of clinical isolate P303 Kim & Weiser (1998)
Escherichia coli
One Shot TOP10 chemically
competent cells
F
2 mcrA D(mrr-hsdRMS-mcrBC) w80lacZDM15 DlacX74 recA1
araD139 D(ara-leu)7697 galU galK rpsL (Sm
r) endA1 nupG
Invitrogen
XL1-Blue supercompetent cells recA1 endA1 gyr96 thi-1 hsdR17 supE44 relA1 lac [F9 proAB
lacl
qZDM15 Tn10 (Tet
r)]
Stratagene
BgaA is a pneumococcal adhesin
http://mic.sgmjournals.org 2371inoculum to neuraminidase-treated cells. Dose dependence was
evaluated by incubating D562 cells in concentrations of rBgaA
ranging from 0.00433 to 4.33 pmol per 1.9 cm
2 well surface area.
Trypan blue staining was used to confirm that purified neuraminidase
and rBgaA were not toxic to epithelial cells. To perform staining, cells
were treated with glycosidases, washed and lifted with trypsin as
described above. Subsequently, 25 ml cells was added to an equal
volume of 0.4% trypan blue. Following incubation at room
temperature for 2–3 min, total numbers of cells and stained cells were
counted by using a haemocytometer.
To determine the role of G-protein-coupled platelet-aggregating factor
receptor (PAFR) in adherence of R6 in our system, we added 1 or
10 mM PAFR antagonist to the bacterial inoculum. The contribution of
proteinaceous receptors to pneumococcal adherence was tested by
preincubating D562 cells with 0.0025% trypsin or 1 mg proteinase K
ml
21 for 10 min at 37 uC. Following treatment, cells werewashed twice
with PBS and adherence assays were performed as described above. To
investigate the role of asialo-GM1, adherence to neuraminidase-treated
D562 cells was determined in the presence of a range of concentrations
of rabbit anti asialo-GM1 (Wako Chemicals) or asialo-GM1.
Labelling of carboxylate-modified FluoSpheres with rBgaA.
rBgaA, glycine (Acros Organics) or BSA were bound covalently to
carboxylate-modified FluoSpheres (Molecular Probes) (505/515 nm
range, yellow, 1 mm in diameter) as described previously (Romero-
Steiner et al., 2006). In brief, the negative charge of the sonicated,
washed, carboxylate-modified FluoSpheres was activated by EDAC
solution (100 mg ml
21) (Molecular Probes). A 250 ml volume of
rBgaA (1 mg ml
21), BSA (0.5 mg ml
21) or glycine (1 M) was added
to the FluoSpheres and incubated overnight at room temperature.
The remaining active sites were blocked by addition of a 1 M solution
of glycine, followed by a 30 min incubation. The FluoSphere
suspension was then washed three times in PBS and the supernatant
of the first wash was saved for protein determinations using a Micro
BCA Protein Assay kit (Pierce).
Adherence of rBgaA-coated FluoSpheres to D562 cells. D562
cells were grown to confluence in 24-well tissue-culture plates and were
pretreated for 30 min with 0.01 U purified C. perfringens neuramini-
dase per 1.9 cm
2 well surface area. Non-treated cells were incubated
with medium alone. The cells were washed once with 0.5 ml PBS
buffer+0.5% BSA per well. Preliminary experiments identified a 1/250
dilution of FluoSpheres in PBS buffer+1% BSA as optimal for
measuring adherence. A 200 ml volume of a sonicated (3 min), diluted
FluoSphere suspension or a no-FluoSphere control was added to the
centre of the washed monolayers and assays were performed as
described previously (Romero-Steiner et al., 2006). In brief, the beads
were allowed to adhere for 2 h at 37 uC( 5%C O 2), the plates were then
washed five times with PBS+0.5% BSA and allowed to dry, and
adherencewas assessedusing afluorometer (485/520 nm).Experiments
were performed in triplicate on three independent occasions.
b-Galactosidase activity assays. b-Galactosidase assays were
performed using a modification of the colorimetric assay using
ONPG as a substrate, as described previously (King et al., 2006).
Assays were performed in triplicate on three independent occasions.
Table 2. Primers used in this study
Group/primer no. Primer sequence (5§A3§)* Location (GenBank
accession no.)
nanA
N.1 TATCGAGTAGGGTAGTTCTT 149–169 (X72967)
N.2 ACGGGGCAGGTTAGTGACAT 1953–1972 (V01277)
N.3 TAGTTCAACAAAGGAAAATTGGATAA 1101–1126 (V01227)
N.4 AGCACGAACTGGAATCTTACCT 1008–1037 (U43526)
Janus
J.1 CCGTTTGATTTTTAATGGATAATG 7–30 (AY334019)
J.2 GGGCCCCTTTCCTTATGCTT 247511–247527 (AE005672)
Plasmid
P.1 GTAAAACGACGGCCAG 391–406D
P.2 CAGGAAACAGCTATGAC 205–221D
bgaA
B.1 AACTAGGTTGTCATACCATG 149–168 (AE007374)
B.2 GTAACTACTAATCCTGCACT 6888–6907 (AE007374)
B.3 ATTGTTCGCCTTACTTTTGATG 683–703 (AF282987)
B.4 ACGGGAGTTTGATTTTGGTTGTG 2161–2183 (AF282987)
B.5 TTCATGTGGTCAATTGGTAATCAAATAGGTGAAGCTAATGGTG 1669–1711 (AF282987)
B.6 CACCATTAGCTTCACCTATTTGATTACCAATTGACCACATGAA 1669–1711 (AF282987)
B.7 TAACGGTAACCAAACAAATCCTTC 1254–1277 (AF282987)
B.8 TAGATGCGATTTTAGAAGTTG 1139–1159 (AF282987)
B.9 TGGCGTCTACATGGATTCTCAAGT 702–725 (AF282987)
B.10 CATTATCCATTAAAGCAAATCAAACGGAATCAATTCGTACAAGGCA
a 1197–1215 (AF282987)
B.11 AAGCATAAGGAAAGGGGCCCGGATGTTGATAAGACTCGCTATG
b 1758–1780 (AF282987)
B.12 TTATGCGGATGAAACACTTAT 129–149 (AF282987)
B.13 ACGGGAGTTTGATTTTGGTTGTG 2161–2183 (AF282987)
*Underlining indicates overhang for splicing by overlap extension to primers J.1
a and J.2
b; bold indicates base change for site-directed mutagenesis.
DLocation is relative to the described 2.1-TOPO sequence (Invitrogen).
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ments and procedureswereconductedaccordingtoprotocolsapproved
by the Research Institute at Nationwide Children’s Hospital
Institutional Animal Care and Use Committee. Nasopharyngeal
colonization was performed essentially as described previously
(McCool & Weiser, 2004). For C06_18 and C06_18DbgaA,6 -t o
8-week-old C57BL/6 mice (Jackson Laboratories) were inoculated
intranasally with approximately 2610
7 mid-exponential-phase organ-
isms.Thedensityofcolonizationwasassessedbyupperrespiratorytract
lavage and quantitative culture for four mice at 36 h. The animal data
are presented as means+SEM (c.f.u. ml
21).
Statistical analysis. b-Galactosidase activity assays and adherence
assays were analysed by two-tailed Student’s t-tests.
RESULTS
BgaA-mediated adherence is not complemented
by exogenous enzyme
Previous data demonstrated that both nanA and bgaA
mutants in R6 were reduced in adherence to the human
upper airway epithelial cell line D562 (King et al., 2006).
Adherence of the nanA mutant (R6DnanA)c o u l db e
complemented by addition of purified neuraminidase
(King et al., 2006). Data demonstrating that the double
mutant (R6DnanADbgaA) could not be complemented, even
partially, by pretreatment with purified neuraminidase
(Fig. 1a) suggest that both NanA and BgaA contribute to
the same mechanism of adherence. Genetic reconstitution of
R6bgaA (R6DbgaA/bgaA+) resulted in adherence not
statistically significantly different from that of R6, confirm-
ing that mutation of bgaA was responsible for the reduction
in adherence observed (Fig. 1b).
Complementationof thenanA mutantwithpurified enzyme
suggests that the enzyme reveals a receptor for adherence. As
NanA and BgaA act sequentially to deglycosylate host
glycans, we initially proposed that b-galactosidase activity
associated with BgaA acts following desialylation to expose
surface receptors on host cells (King et al., 2006). To test this
hypothesis, we pretreated epithelial cells with neuraminidase
and rBgaA. If BgaA was exposing a receptor for adherence,
then pretreatment of epithelial cells would be expected to
complement the bgaA mutant phenotype; however, neither
R6DbgaA nor R6DnanADbgaA was complemented (Fig. 1c
and data not shown). Furthermore, rBgaA reduced adher-
ence of the parental strain to a level not statistically
significantly different from that of the BgaA mutant
(R6DbgaA), even though we would have expected no change
or perhaps an increase in adherence. Together, these data
suggest an alternative role for BgaA in adherence.
The role of BgaA in adherence is independent of
its enzymic activity
To start elucidating the role of BgaA in adherence, we
investigated whether its b-galactosidase activity wasrequired
for efficient bacterial adherence. Enzymic activity is
predicted to be encoded within the N-terminal domain,
between aa 132 and 966, which shares significant sequence
similarity with other sequenced b-galactosidases (Fig. 2a).
Previous work in E. coli demonstrated that mutagenesis of
the conserved glutamic acid residue 461 resulted in a 1000–
7000-foldreductioninactivityrelativetothewild-typeanda
reduction in substrate binding (Baderet al., 1988; Cupples &
Miller,1988; Cupplesetal.,1990; Gebleretal.,1992; Richard
et al., 1996). Sequence analysis revealed a corresponding
glutamic acid residue in S. pneumoniae, glutamic acid-564,
and site-directed mutagenesis of this residue to glutamine
(Fig. 2a) resulted in a strain, R6BgaAE564Q, that lacked all
detectable b-galactosidase activity (Fig. 2b). Adherence of
R6BgaAE564Q to D562 cells was significantly higher than
that of R6Sm
rDbgaA (P¡0.01; Fig. 2c). These data
demonstrate that the role of BgaA in adherence is in-
dependent of b-galactosidase activity.
BgaA blocks pneumococcal binding to epithelial
cells
Pretreatment of epithelial cells with exogenous b-
galactosidase reduced adherence of the R6 parental strain
to a level not statistically significantly different from that of
R6DbgaA (Fig. 1a). This reduction in adherence could be
explained by the binding of rBgaA to bacterial receptors
exposed by neuraminidase on the epithelial-cell surface,
thereby blocking the ability of native BgaA on the bacterial-
cell surface to mediate adherence. One interpretation of
these data is that BgaA is acting as an adhesin.
To investigate this possibility, a competition assay was
performed: a range of rBgaA concentrations was added to
neuraminidase-treated epithelial cells at the same time as
the R6 parental strain. Adherence was blocked in a dose-
dependent manner and by as little as 0.043 pmol rBgaA per
1.9 cm
2 well surface area (Fig. 3). This amount of rBgaA
possesses b-galactosidase activity in tissue-culture medium
not statistically significantly different from that produced by
the number of bacteria added to our adherence assays and
suggests a physiological relevance to these experiments. We
confirmed that rBgaA had no toxic effect on S. pneumoniae
or the epithelial cells by enumerating non-adherent bacteria
and assessing the viability of monolayers (data not shown).
BgaA binds directly to human epithelial cells
To further minimize the variables in the study of bacterial
adherence, we compared the binding of FluoSpheres
(Invitrogen) coated with rBgaA, glycine or BSA to untreated
or neuraminidase-treated epithelial cells (Fig. 4). The
adherence of BgaA-coated beads to neuraminidase-treated
epithelial cells was at least 47.7% higher than that of beads
coated with BSA or glycine, thereby demonstrating that BgaA
binds directly to human epithelial cells. In addition, treatment
of the epithelial cells with neuraminidase increased the
binding of BgaA-coated beads by at least 48.3%, further
supporting a role for pneumococcal neuraminidase in
exposing a cell-surface receptor that mediates adherence.
BgaA is a pneumococcal adhesin
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increase in adherence of all FluoSpheres, possibly due to the
reduction of negatively charged sialic acid on the cell surface.
Initial characterization of the BgaA receptor
Several pneumococcal adherence mechanisms have been
elucidated. As R6 does not encode the adhesive pili, these
do not contribute to adherence of this strain (Bagnoli et al.,
2008; Hoskins et al., 2001). In addition, the glycosidase-
dependent mechanism of adherence was shown to be
independent of both the binding of phosphorylcholine on
the bacterial cell to the PAFR, and the binding of CbpA to
the polymeric immunoglobulin (Ig) receptor, as neither
the R6DcbpA strain nor treatment with PAFR inhibitor
reduced adherence in our models (data not shown)
(Cundell et al., 1996; Zhang et al., 2000).
To determine whether BgaA is binding to a proteinaceous
receptor, epithelial cells were pretreated with protease. Pre-
treatmentofcellswithtrypsindidnotreducetheadherenceof
R6; in fact, a statistically significant increase in adherence was
observed (P¡0.01; Fig. 5a). These data suggest that R6 is
binding to a non-proteinaceous receptor that is exposed more
efficiently on the epithelial-cell surface following the removal
of proteins. Furthermore, in this model system, the residual
adherence of the BgaA mutant does not appear to be due to a
Fig. 1. Determination of whether glycosidases can complement the adherence of pneumococcal glycosidase mutants. R6 and
R6 exoglycosidase mutants were grown to an OD600 of 0.6 and their relative adherence to D562 cells was determined.
Adherence is expressed in comparison to the percentage adherence of parental strain R6 over a 60 min incubation period
under the same conditions. Values are means±SD of three independent experiments. (a) Purified neuraminidase complements
the adherence of a nanA mutant, but not a nanA bgaA double mutant, to human epithelial cells in culture. N indicates that D562
cells were pretreated for 30 min with 0.01 U purified C. perfringens neuraminidase per 1.9 cm
2 well surface area. *Statistically
significant difference (P¡0.02) between R6 and both R6DnanA and R6DnanADbgaA. **Statistically significant difference
between R6DnanA and R6DnanA+N( P¡0.02). (b) Reconstitution of bgaA restores adherence. All D562 cells were
pretreated for 30 min with 0.01 U purified C. perfringens neuraminidase per 1.9 cm
2 well surface area. *Statistically significant
difference (P¡0.0001) between R6 and R6DbgaA. (c) Purified neuraminidase and rBgaA do not complement bgaA mutants.
All D562 cells were pretreated for 30 min with 0.01 U purified C. perfringens neuraminidase per 1.9 cm
2 well surface area.
Where indicated (+B), neuraminidase treatment was followed by pretreatment with rBgaA at 4.33 pmol per 1.9 cm
2 well
surface area for 30 min. *Statistically significant difference (P¡0.05) between R6 and R6+B, R6DbgaA and R6DnanADbgaA.
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adherence of R6DbgaA significantly. Pretreatment of cells
with proteinase K (1 mg ml
21) showed similar results (data
not shown).These datasuggest that thereceptoris likely tobe
a glycan in the context of a glycosphingolipid.
S. pneumoniae has previously been proposed to bind to the
glycosphingolipid asialo-GM1 (Krivan et al., 1988).
However, whether S. pneumoniae binds to this structure
on epithelial cells or what may serve as the bacterial
adhesin has not been determined. To determine whether
R6 binds to asialo-GM1, adherence assays were performed
following the pre-incubation of neuraminidase-treated
epithelial cells with anti-asialo-GM1 (Fig. 5b). Addition
of this antibody was shown previously to reduce adherence
of bacteria that utilize asialo-GM1 as an adhesin (de
Bentzmann et al., 1996). However, no statistically signific-
ant reduction in adherence of R6 or R6DbgaA was
observed. These data suggest that R6 does not bind to
asialo-GM1 under these assay conditions. Furthermore,
adherence to epithelial cells was not reduced when bacteria
were pre-incubated with asialo-GM1 (data not shown).
Together, these data suggest that S. pneumoniae binds to a
glycosphingolipid, but not asialo-GM1.
BgaA contributes to adherence of encapsulated
pneumococci to epithelial cells of different
origins
R6 is an unencapsulated strain of S. pneumoniae. Whilst
there is evidence that S. pneumoniae expresses lower levels,
Fig. 2. The role of BgaA in adherence is independent of its b-galactosidase activity. (a) Schematic representation of the
published sequence of BgaA. Numbering refers to the amino acid locations in the published sequence, starting at the first
putative methionine within the R6 bgaA published sequence (GenBank accession no. NC_003098; Hoskins et al., 2001) and
locations of conserved domains indicated: glycosyl hydrolase family 2 domain, bacterial Ig-like domains (Big) and the G5
domain. Nucleotide and amino acid sequences are given for regions flanking the site-directed mutation introduced to the BgaA
active site. The mutated nucleotide and the resulting amino acid change are shown in bold beneath the parent sequence.
(b) R6BgaAE564Q lacks detectable b-galactosidase activity. Aliquots of cultures, grown to an OD600 of 0.6, were lysed with
toluene and activity was measured using the colorimetric substrate ONPG. Values are means±SD of three independent
experiments. (c) R6BgaAE564Q is not significantly reduced in adherence compared with the parental strain R6Sm
r. Bacterial
strains were grown to an OD600 of 0.6 and their relative adherence to D562 cells was determined. Adherence is expressed in
comparison to the percentage adherence of parental strain R6 over a 60 min incubation period under the same conditions.
Values are means±SD of three independent experiments. *Statistically significant difference (P¡0.01) between R6Sm
r and
R6Sm
rDbgaA (b, c) and R6BgaAE564Q (b). **Statistically significant difference (P¡0.01) between R6BgaAE564Q and both
R6Sm
r and R6Sm
rDbgaA.
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of the upper airway, expression of the capsular polysac-
charide is required for the ability of the bacterium to cause
invasive disease (Hammerschmidt et al., 2005; Kim et al.,
1999; Watson & Musher, 1990). We therefore demon-
strated that a mutant in D39 (D39DbgaA), the encapsulated
progenitor strain of R6, was also statistically significantly
reduced in adherence to D562 cells compared with the
parental strain (P¡0.01; Fig. 6a).
We also wanted to investigate the contribution of BgaA to
adherence of more recent isolates; therefore, we generated
BgaA mutants in C06_18, 384 and TIGR4. Mutation of
bgaA statistically significantly reduced adherence of one of
the three strains: C06_18, a low-passage serotype 22F strain
isolated from blood (P¡0.01; Fig. 6b and data not shown).
A second independent mutant generated in this strain
background showed the same phenotype, thereby con-
firming that mutation of bgaA was responsible for the
observed phenotype. To further support the hypothesis
that BgaA contributes to adherence of C06_18, we
confirmed that addition of rBgaA statistically significantly
reduced adherence of this strain (P¡0.002). Together,
these data suggest that BgaA acts as an adhesin for at least
some clinical isolates (Fig. 6c).
As D562 cells represent only a small fraction of the human
airway at best, similar experiments were performed using a
human lung carcinoma cell line, A549, and an immortalized
human bronchial epithelial cell line, 16HBE14 (Fig. 6b). The
level of adherence of C06_18 to each of these cell lines was
different, perhaps suggesting the differential distribution of
receptors on the epithelial-cell surface (mean adherence of
C06_18 to D562, 2.0±1.1610
4 per well; to 16HBE14,
4.9±4.5610
4 per well; and to A549, 1.2±2.8610
4 per
well). However, when compared with the parental strain,
C06_18DbgaA showed a statistically significant reduction in
adherence to all three human cell lines (P¡0.01).
The BgaA mutant (C06_18DbgaA) showed no reduction in
ability to colonize mice compared with the parental strain
[C06_18, 4.75±0.67610
4; C06_18DbgaA, 5.64±1.65610
4
(ml lavage fluid)
21]. This suggests that the receptor may be
human-specific. The demonstration that C06_18DbgaA
was not reduced in adherence to a neuraminidase-treated
mouse airway epithelial cell line, LA-4 (Fig. 6b; C06_18,
1.7±1.7610
4; C06_18DbgaA, 2.1±2.2610
4 per well),
further supports this hypothesis (Stoner et al., 1975).
As immortalization of cells can lead to changes in expression
of surface molecules, including receptors (Edwards et al.,
2001), we also demonstrated that C06_18DbgaA was
statistically significantly reduced (60%) in adherence to
primary normal human bronchial epithelial cells (P¡0.01;
mean adherence of C06_18 to NHBEs, 5.65±8.5610
4 per
well)(Lonza)(Fig. 6b). In additiontoC06_18,R6DbgaAwas
also shown to have statistically significantly reduced
adherence to immortalized and primary human epithelial
cells (P¡0.01; data not shown). Together, these data suggest
that BgaA contributes to adherence of recent clinical isolates
to human airway epithelial cells of different origins.
Fig. 3. rBgaA competitively inhibits adherence of R6 to human
epithelial cells in culture. R6 and R6DbgaA were grown to an
OD600 of 0.6 and their relative adherence to D562 cells was
determined. All D562 cells were pretreated for 30 min with 0.01 U
purified C. perfringens neuraminidase per 1.9 cm
2 well surface
area. Indicated amounts of rBgaA per 1.9 cm
2 well surface area
were added to the bacterial inoculum (+B). Adherence is
expressed in comparison to the percentage adherence of parental
strain R6 over a 60 min incubation period under the same
conditions. Values are means±SD of three independent experi-
ments. *Statistically significant difference (P¡0.05) between R6,
and R6+B and R6DbgaA.
Fig. 4. Relative binding of FluoSpheres (Invitrogen) coated with
rBgaA, BSA or glycine to human epithelial cells in culture. Where
indicated, D562 cells were pretreated for 30 min with 0.01 U
purified C. perfringens neuraminidase (+N) per 1.9 cm
2 well
surface area. One hundred microlitres of a 1/1000 dilution of
beads was added to each well and plates were incubated at 37 6C
for 2 h. Plates were washed and dried, and binding was assessed
by measuring fluorescence (528 nm). Shown is a representative of
three independent experiments. Values are means±SD of three
wells.
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Carbohydrate modification plays an essential role in
pneumococcal pathogenesis; carbohydrates are required
for growth of the bacteria and compose the pneumococcal
capsule, which is essential for disease. The finding that BgaA
probably acts as an adhesin supports the hypothesis that
pneumococcal glycosidases contribute to colonization
independently of their enzymic activity. This hypothesis is
also supported by the recent finding that the lectin-like
domain of NanA promotes pneumococcal adherence and
invasion of human brain microvascular endothelial cells
(Uchiyama et al., 2009). Our current study indicates that
NanA reveals a receptor on airway epithelial cells. Together,
these findings suggest distinct roles for NanA in adherence
to different cell types, probably due to the differential
distribution of receptors.
Pneumococcal adherence appears to be complex. Several
mechanisms of pneumococcal adherence have been iden-
tified previously (Cundell et al., 1995b; Hammerschmidt,
2006; Zhang et al., 2000). Given the importance of bacterial
adherence to colonization and differentstagesof disease, it is
not surprising that S. pneumoniae possesses multiple
adherence mechanisms. Adding another layer of complexity
is the fact that the expression of some pneumococcal
adhesins differs between strains (Bagnoli et al., 2008;
Moschioni et al., 2008; Paterson & Mitchell, 2006).
Furthermore, it is likely that different host cells vary in
their expression of receptors for adherence. Thus, we can
predict that the relative contribution of different mechan-
isms to adherence is probably dependent on both the host-
cell type and the pneumococcal strain. We demonstrated
that bgaA contributed significantly to adherence of R6, D39
and C06_18. The residual adherence observed is probably
due to expression of other adherence mechanisms. We were
unable to demonstrate a phenotype for two further strains,
TIGR4 and 384. It is unknown whether these strains express
other adherence mechanisms that compensate completely
for the absence of BgaA or whether this protein does not
contributetoadherenceofthesestrains.Ourdata allowusto
concludethat BgaAcontributestoadherenceofatleastsome
pneumococcal strains to all airway epithelial cells tested,
including primary NHBE cells.
Our experiments demonstrated that rBgaA inhibited
pneumococcal adherence and bound directly to epithelial
cells, both key characteristics of adhesins. Analysis of the
BgaA sequence reveals features supporting the hypothesis
that this protein may have functions besides that of a
b-galactosidase (Fig. 2a). BgaA is approximately twice the
size of the majority of other predicted b-galactosidases. The
N-terminal region of the protein (aa 110–1136) shares
significant sequence similarity with other b-galactosidases,
but the C-terminal half of the protein, with the exception of
the surface-localization marker, has no known function and
lacks sequence similarity to most predicted b-galactosidases.
The uncharacterized, predicted b-galactosidases from some
other streptococcal species, including Streptococcus oralis
(ATCC 35037
T; AEDW01000000), Streptococcus mitis
(ATCC 6249; AEEN01000000), Streptococcus sanguinis
(ATCC 49296; AEPO01000000) and Streptococcus gordonii
(Vickerman et al., 2007), are approximately the same length
as BgaA and share high levels of amino acid identity over
2166 aa. Whether BgaA is a member of a novel family of
b-galactosidase adhesins is unknown.
Fig. 5. Studies to determine the nature of the epithelial-cell receptor for BgaA. R6 and R6 exoglycosidase mutants were grown to
an OD600 of 0.6 and their relative adherence to D562 cells was determined. Adherence is expressed in comparison to the
percentage adherence of parental strain R6 over a 60 min incubation period under the same conditions. Values are means±SD of
threeindependentexperiments. (a) Trypsintreatmentdoes notalter the adherenceofR6 toairwayepithelialcells.Whereindicated
(+), epithelial cells were pretreated with 200 ml 0.0025% trypsin. *Statistically significant difference (P¡0.01) between R6 and
R6+trypsin. (b) Addition of anti-asialo-GM1 does not reduce R6 adherence. All cells were pretreated for 30 min with 0.01 U
purified C.perfringensneuraminidaseper1.9 cm
2well surfacearea.Theconcentrationsofanti-asialo-GM1 indicatedwere added
to the inoculum.
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unknown. The C-terminal region may confer the Galb1,
4GlcNAc enzyme specificity or perform a second inde-
pendent function, for example mediating adherence.
Homology searches using the C terminus of BgaA did
not reveal a function for this region; however, it does
contain an 80 aa partial G5 domain (aa 2083–2162). G5
domains are present in many enzymes that bind GlcNAc
and have been proposed to contribute to this binding
(Bateman et al., 2005). This G5 domain may contribute to
BgaA-mediated adherence, either directly by enabling
binding to surface-associated GlcNAc or indirectly by
contributing to the restricted cleavage specificity of BgaA.
This may in turn enable BgaA to adhere to glycan
substrates that it is unable to cleave. G5 domains present
in staphylococcal surface proteins have also been proposed
to mediate intercellular adhesion, although a single repeat
was insufficient for this activity (Conrady et al., 2008).
Also, within the C-terminal region are several bacterial Ig
folds (pfam07532), which are often identified in both
glycosidases and other surface proteins (Marchler-Bauer
et al., 2007). The role of the G5 domain and Ig folds will be
the focus of further research.
Generation of the active-site mutant R6BgaAE564Q
demonstrated that residue 564 is essential for enzymic
activity and confirmed that b-galactosidase activity is not
required for BgaA to mediate pneumococcal adherence.
Mutation of the corresponding residue in E. coli was
reported to reduce substrate binding (Cupples et al., 1990);
however, it is unknown whether this is true in S.
pneumoniae. R6BgaAE564Q adhered to epithelial cells at
a significantly higher level than the parental strain, raising
several possibilities for the increased adherence. If the
active site is responsible for adherence and the glutamine
substitution at aa 564 does not reduce substrate binding,
Galb1,4GlcNAc could act as an additional receptor on the
epithelial-cell surface. Alternatively, if the region mediating
adherence is distinct from the active site, it is possible that
the substrate is still bound efficiently and that the inability
to cleave this linkage may provide more time for increased
interaction between the adhesin and receptor. A third
possibility is that substrate binding is reduced, and that
BgaA which is not interacting with the substrate has
increased ability to bind to the receptor.
The receptor for BgaA on the epithelial surface is currently
unknown. Previous studies have reported that S. pneumo-
niae adheres to a number of different host-cell glycoconju-
gates, including GalNAcb1,4Gal found in ganglioside GM1
(Krivan et al., 1988).However,our studies suggestthat BgaA
is binding to the glycan portion of a glycosphingolipid, but
not GM1. It has previously been proposed that the initial
adherence of S. pneumoniae to resting epithelial cells is
mediated by a glycoconjugate receptor (Cundell et al.,
1995a; Hammerschmidt, 2006); therefore, NanA and BgaA
may contribute to the initial adherence of S. pneumoniae to
human epithelia. Mutation of bgaA was shown previously to
have a small but significant effect in a model of pneumonia,
but the role of this protein in colonization wasnot examined
(Robertson et al., 2002). We observed no reduction in the
ability of a bgaA mutant to colonize the oro-nasopharynx or
to bind to mouse airway epithelial cells, suggesting that the
BgaA receptor is human-specific.
Collectively, these data support the hypothesis that
pneumococcal glycosidases have functions independent of
their enzymic activity. Glycosidases are probably upregu-
lated during colonization, as the concentration of free
carbohydrates in the nasopharynx is normally low and the
Fig. 6. BgaA contributes to the adherence of encapsulated
pneumococci to human epithelial cells. Bacterial strains were
grown to an OD600 of 0.6. Adherence is expressed relative to the
adherence of the parental strain over a 60 min incubation period
under the same conditions. Values are means±SD of three
independent experiments. (a) Relative adherence of D39 and
D39DbgaA to D562 epithelial cells in culture. *Statistically
significant difference (P¡0.01) between the relative adherence
of D39DbgaA and its parental strain. (b) Relative adherence of
C06_18DbgaA to epithelial cells in culture. The relative adherence
of C06_18DbgaA to D562, A549, HBE, NHBE and LA-4 epithelial
cells was determined. *Statistically significant difference (P¡0.01)
between the relative adherence of C06_18DbgaA and its parental
strain. (c) rBgaA significantly reduces adherence of an encapsu-
lated recent clinical isolate. Where indicated (+B), 4.33 pmol
rBgaA per 1.9 cm
2 well surface area was added to the bacterial
inoculum. *Statistically significant difference (P¡0.002) between
the relative adherence of C06_18 in the presence of rBgaA.
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for these proteins may efficiently co-ordinate growth and
other processes, including adherence, that are required to
establish and maintain colonization.
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